Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Provention Bio Inc (NQ: PRVB ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 26, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Provention Bio Inc < Previous 1 2 3 4 5 6 7 8 9 Next > Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company? June 15, 2023 Company Moves Ahead With Drug Development Via Benzinga Provention Bio Inc. (NASDAQ: PRVB) Highlighted for Surprising Price Action April 26, 2023 Via Investor Brand Network Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis April 19, 2023 Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... Via Benzinga Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise April 12, 2023 Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... Via Benzinga Is Sanofi Stock a Buy Now? March 25, 2023 The pharma giant has outperformed the broader market over the past 12 months. Via The Motley Fool Provention Bio's Earnings Outlook March 15, 2023 Via Benzinga 4 Analysts Have This to Say About Provention Bio March 14, 2023 Via Benzinga Provention Bio, Inc. (NASDAQ: PRVB) Making Surprising Moves in Monday Session March 13, 2023 Via Investor Brand Network Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information April 11, 2023 Via Benzinga PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB March 29, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL) March 23, 2023 From Brodsky & Smith LLC Via GlobeNewswire Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi March 13, 2023 Via Benzinga Top 5 Health Care Stocks That May Crash In March March 22, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review March 17, 2023 A market rally is underway, but bank stocks kept tumbling. Via Investor's Business Daily Why Provention Bio Stock Skyrocketed 256% This Week March 16, 2023 Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker. Via The Motley Fool Why Shares of MacroGenics Climbed Thursday March 16, 2023 The cancer-focused biotech delivered a strong earnings report. Via The Motley Fool Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2023 March 15, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 March 14, 2023 Via Benzinga Top 5 Health Care Stocks That Are Ticking Portfolio Bombs March 14, 2023 The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. Via Benzinga PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB March 13, 2023 From Kahn Swick & Foti, LLC Via Business Wire Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners March 13, 2023 On a volatile market day, companies are still looking for smart combinations. Via The Motley Fool Nasdaq Up 150 Points; Gold Rises Over 2% March 13, 2023 U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 150 points on Monday. The Dow traded up 0.59% to 32,096.68 while the NASDAQ rose 1.35% to 11,288.8. The S&P... Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL) March 13, 2023 From Brodsky & Smith LLC Via GlobeNewswire Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion March 13, 2023 Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and Via Spotlight Growth 12 Health Care Stocks Moving In Monday's Intraday Session March 13, 2023 Via Benzinga Dow Jumps 300 Points; Crude Oil Down 1% March 13, 2023 U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 300 points on Monday. The Dow traded up 0.94% to 32,210.33 while the NASDAQ rose 1.52% to 11,307.74. The S&P 500,... Via Benzinga Illumina, Seagen And Other Big Stocks Moving Higher On Monday March 13, 2023 U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session. Via Benzinga Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session March 13, 2023 Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. Via Benzinga US Stocks Mostly Higher; Dow Rises 75 Points March 13, 2023 U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose... Via Benzinga Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal March 13, 2023 Pfizer expects Seagen to add at least $10 billion to its topline in 2030. Via Investor's Business Daily < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
